香港股市 已收市

Pfizer Inc. (PFE)

NYSE - Nasdaq 即時價格。貨幣為 USD。
加入追蹤清單
25.48+0.22 (+0.88%)
市場開市。 截至 09:44AM EDT。

Pfizer Inc.

66 Hudson Boulevard East
New York, NY 10001-2192
United States
212 733 2323
https://www.pfizer.com

版塊Healthcare
行業Drug Manufacturers - General
全職員工88,000

高階主管

名稱頭銜支付行使價出生年份
Dr. Albert Bourla D.V.M., Ph.D.Chairman of the Board & CEO4.05M1962
Mr. David M. DentonChief Financial Officer & Executive VP1.75M1965
Dr. Mikael Dolsten M.D., Ph.D.Chief Scientific Officer and President of Research & Development2.41M1958
Mr. Douglas M. LanklerExecutive VP & General Counsel1.76M1966
Mr. Aamir MalikExecutive VP & Chief U.S. Commercial Officer1.89M1976
Ms. Jennifer B. DamicoSenior VP, Controller & Principal Accounting Officer1968
Ms. Lidia L. FonsecaExecutive VP and Chief Digital & Technology Officer1969
Ms. Francesca M. DeMartinoChief Investor Relations Officer
Mr. Rady A. JohnsonExecutive VP and Chief Compliance, Quality & Risk Officer1962
Mr. Andreas J. PanayiotouGlobal Chief Marketing Officer
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

公司管治

截至 2024年4月1日 止,Pfizer Inc. 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中:10;董事會:6;股東權利:1;現金賠償:3。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。